GB201121794D0 - PIM kinase inhibitors - Google Patents
PIM kinase inhibitorsInfo
- Publication number
- GB201121794D0 GB201121794D0 GBGB1121794.0A GB201121794A GB201121794D0 GB 201121794 D0 GB201121794 D0 GB 201121794D0 GB 201121794 A GB201121794 A GB 201121794A GB 201121794 D0 GB201121794 D0 GB 201121794D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- ring
- optionally substituted
- sulfur
- absent
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- -1 1,3-thiazolyl Chemical group 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 241000713869 Moloney murine leukemia virus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001566 pro-viral effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound of formula I or II or a salt, hydrate or solvate thereof: wherein R1 is hydrogen or a substituent; Y is sulfur or NRb where Rb is hydrogen or (1-3C)alkyl; ring A is either (i) an optionally substituted 5-membered heteroaryl ring comprising a nitrogen atom and one or more heteroatoms selected from nitrogen, oxygen and sulfur, or (ii) an optionally substituted 5-membered heteroaryl ring; L is a chain linker or is absent; ring B is optionally substituted and is selected from (4-7C)cycloalkyl, heteroaryl, heterocyclyl and aryl. Preferably, Y is sulfur, ring A is selected from 1,3-thiazolyl, 1,3-oxazolyl and pyridyl, L is either absent or is N(Me)C(O)- and ring B is selected from optionally substituted phenyl and substituted pyridyl. The compounds of formula I or II inhibit PIM (Proviral Integration site for the Moloney murine leukemia virus) kinase and may be useful in the treatment and/or prevention of proliferative disorders, such as cancer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1121794.0A GB201121794D0 (en) | 2011-12-19 | 2011-12-19 | PIM kinase inhibitors |
| GB1222826.8A GB2497858A (en) | 2011-12-19 | 2012-12-18 | Substituted heterocyclic compounds and their use as PIM kinase inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1121794.0A GB201121794D0 (en) | 2011-12-19 | 2011-12-19 | PIM kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201121794D0 true GB201121794D0 (en) | 2012-02-01 |
Family
ID=45572629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1121794.0A Ceased GB201121794D0 (en) | 2011-12-19 | 2011-12-19 | PIM kinase inhibitors |
| GB1222826.8A Withdrawn GB2497858A (en) | 2011-12-19 | 2012-12-18 | Substituted heterocyclic compounds and their use as PIM kinase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1222826.8A Withdrawn GB2497858A (en) | 2011-12-19 | 2012-12-18 | Substituted heterocyclic compounds and their use as PIM kinase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB201121794D0 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239853A1 (en) * | 2004-02-04 | 2005-10-27 | Tjeerd Barf | New compounds |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| TW200745066A (en) * | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
| KR20100137557A (en) * | 2008-04-04 | 2010-12-30 | 아이알엠 엘엘씨 | Compounds and Compositions as ITP inhibitors |
| KR20120024619A (en) * | 2009-04-20 | 2012-03-14 | 에스비아이 바이오테크 가부시키가이샤 | Thiazolidinone derivative |
-
2011
- 2011-12-19 GB GBGB1121794.0A patent/GB201121794D0/en not_active Ceased
-
2012
- 2012-12-18 GB GB1222826.8A patent/GB2497858A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB201222826D0 (en) | 2013-01-30 |
| GB2497858A (en) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890594A1 (en) | Aryl, Heteroaryl, and Heterocyclic Compounds for the Treatment of Disorders | |
| NZ746607A (en) | Substituted reverse pyrimidine bmi-1 inhibitors | |
| PH12018500610B1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| MY192109A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| NZ704738A (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
| WO2010055304A3 (en) | Oxazole or imidazole derivatives for use in the treatment of autoimmune disesases, in particular multiple sclerosis | |
| NZ703714A (en) | 2-aminopyrazine derivatives as csf-1 r kinase inhibitors | |
| MA34064B1 (en) | HETEROCYCLIC COMPOUND | |
| GEP20227353B (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| ZA201902335B (en) | Pharmaceutical compounds | |
| WO2011141716A3 (en) | Modulators of chk-1 activity | |
| PH12018500626B1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| EA201290073A1 (en) | UREA COMPOUNDS CONTAINING 5,6-BICYCLIC HETEROARYL AS KINAZ INHIBITORS | |
| EP4122924A3 (en) | Compounds and the use thereof in metathesis reactions | |
| IN2014DN07283A (en) | ||
| EA201600403A1 (en) | N-ACYLIMINOHETEROCYCLIC COMPOUNDS | |
| MX2017009624A (en) | Pyridazinone macrocycles as irak inhibitors and uses thereof. | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| MX341341B (en) | Benzamide derivatives and their use as hsp90 inhibtors. | |
| EA201791816A1 (en) | KV1.3 INHIBITORS AND THEIR APPLICATION IN MEDICINE | |
| EP2602254A4 (en) | HETEROCYCLIC COMPOUND | |
| MX366633B (en) | New anti-invasive compounds. | |
| BR112018010812A2 (en) | 1,3,4-thiadiazole compounds and their use in cancer treatment | |
| UA117681C2 (en) | N-acylimino heterocyclic compounds | |
| MD4215B1 (en) | Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |